BRIEF-Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition

Reuters12-08 21:07

BRIEF-<a href="https://laohu8.com/S/NRIX">Nurix Therapeutics</a> Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition

Dec 8 (Reuters) - Nurix Therapeutics Inc NRIX.O:

NURIX THERAPEUTICS PRESENTS NEW DATA FROM THE PHASE 1 TRIAL OF BEXOBRUTIDEG (NX-5948) IN WALDENSTRÖM MACROGLOBULINEMIA AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY $(ASH)$ ANNUAL MEETING AND EXPOSITION

Source text: ID:nGNX8klpjp

Further company coverage: NRIX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589353672?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589353672","market":"fut","top_or_hot":-1,"title":"BRIEF-Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Nurix <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>NRIX.O</span>:</p><ul><li><p>NURIX THERAPEUTICS PRESENTS NEW DATA FROM THE PHASE 1 TRIAL OF BEXOBRUTIDEG (NX-5948) IN WALDENSTRÖM MACROGLOBULINEMIA AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> ANNUAL MEETING AND EXPOSITION</p></li></ul><p>Source text: <span>ID:nGNX8klpjp</span></p><p>Further company coverage: <span>NRIX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And Exposition</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Nurix <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>NRIX.O</span>:</p><ul><li><p>NURIX THERAPEUTICS PRESENTS NEW DATA FROM THE PHASE 1 TRIAL OF BEXOBRUTIDEG (NX-5948) IN WALDENSTRÖM MACROGLOBULINEMIA AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> ANNUAL MEETING AND EXPOSITION</p></li></ul><p>Source text: <span>ID:nGNX8klpjp</span></p><p>Further company coverage: <span>NRIX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUABJG6V8:1","article_id":"2589353672","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589353672","pubTimestamp":1765199238,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenstrm Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And ExpositionDec 8 (Reuters","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NRIX":"Nurix Therapeutics"},"translate_title":"简介-Nurix Therapeutics在第67届美国血液学会年会暨博览会上展示了Bexobrutideg治疗Waldenströ巨球蛋白血症1期试验的新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":0.9},"content_text":"BRIEF-Nurix Therapeutics Presents New Data From The Phase 1 Trial Of Bexobrutideg In Waldenström Macroglobulinemia At The 67th American Society Of Hematology Annual Meeting And ExpositionDec 8 (Reuters) - Nurix Therapeutics Inc NRIX.O:NURIX THERAPEUTICS PRESENTS NEW DATA FROM THE PHASE 1 TRIAL OF BEXOBRUTIDEG (NX-5948) IN WALDENSTRÖM MACROGLOBULINEMIA AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY $(ASH)$ ANNUAL MEETING AND EXPOSITIONSource text: ID:nGNX8klpjpFurther company coverage: NRIX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589353672","isCrawlerRequest":true}